

- **Name:** Sun Min Lim
 - **Current Position & Affiliation:** Assistant Professor
 - **Country:** Republic of Korea
-
- **Educational Background:**
 - 2010.9 ~ 2017.2: Doctor of Philosophy, Yonsei University Graduate School
 - 2002.3 ~ 2008.2: College of Medicine, Yonsei University, Seoul, Republic of Korea
 - 2006.1 ~ 2006.2: Washington University School of Medicine, St Louis, Missouri (Visiting student)
 - **Professional Experience:**
 - 2008.3 ~ 2009.2: Internship, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
 - 2009.3 ~ 2013.2: Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
 - 2012.3~ 2013.2: Chief medical resident, Department of Internal medicine, Severance Hospital
 - 2013.3~2015.8: Fellow, Division of Medical Oncology, Department of Internal Medicine, Severance Hospital
 - 2015.9~2020.2: Assistant Professor, CHA Bundang Medical Center, CHA University
 - 2020.3~ current: Assistant Professor, Severance Hospital, Yonsei University Health System
 - **Professional Organizations:**
 - 2012~: Member, American Society of Clinical Oncology
 - 2012~: Member, American Association of Cancer Research
 - 2012~: Member, Korean Association for Clinical Oncology
 - 2012~: Member, Korean Cancer Study Group
 - 2013~: Member, International Association for the Study of Lung Cancer
 - **Main Scientific Publications:**
 1. Lim, SM*, Chang H*, Cha YJ*, et al. Validation of ALK/ROS1 Dual Break Apart FISH Probe in non-small-cell lung cancer. *Lung Cancer* 2017;111:79-83.
 2. Soo RA, Lim SM, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. *Lung Cancer* 2018;115:12-20.
 3. Yun MR*, Lim SM*, et al. Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors. *Cancer Res* 2018; 78(12):3350-3362.
 4. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. *Cancer Treat Rev* 2018; 65: 1-10.
 5. Lim SM*, Cho SH*, Hwang IG*, et al. Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma. *Cancer Res Treat*

2018 [Epub]

6. Kim MH, Lim SM, Lee K, Soo RA, Cho BC. Can we prevent resistance to osimertinib? Combination or sequential. *J Thoracic Oncol* 2018; 13(7): 877-879.
7. Pho KY, Kim JH, Lee JM, Kim SE, Cho JS, Lim SM*, Cho BC*. Promising preclinical platform for evaluation of immune-oncology drugs using Hu-PBL-NSG lung cancer models. *Lung Cancer* 2019;127:112-121.
8. Lim SM, Choi JW, Hong MH, et al. Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. *Lung Cancer* 2019;131:139-146.
9. Hwang S, Kwon A-Y, Jeong J-Y, Kim S, Kang H, Park J, Kim J-H, Han OJ, Lim SM*, An HJ*. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. *Scientific Reports*. 2020;10:643.
10. Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small cell lung cancer: current landscape and future perspectives. *Immune Netw* 2020;20(1):1-14.
11. Pyo K-H*, Lim SM*, Park C-W*, et al. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. *Journal for ImmunoTherapy of Cancer* 2020;8:e000970.
12. Yang Y-M, Jang Y, Lee SH, Kang B, Lim SM. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. *Lung Cancer* 2020; 146: 70-77.
13. Lim SM, Kim S-W, et al. Real world experience of nivolumab in non-small cell lung cancer in Korea. *Cancer Res Treat* 2020 ; 52(4): 1112-1119.
14. Lim SM, Hong MH, et al. Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. *Journal of Cancer Research and Clinical Oncology* 2021 [Epub]
15. Ahn BC, Zhu VW, Lim SM. The next target for NSCLC: Let it be “RET”. *Journal of Thoracic Oncology* 2020; 15(12): 1803-1805.
16. Kim CG, Cho BC and Lim SM. Sequencing of MET inhibitors in Lung cancer: Have we met the target? *Journal of Thoracic Oncology* 2021; 16(5): 709-711.
17. Kim A*, Lim SM*, Kim JH, Seo JS. Integrative genomic and transcriptomic analyses of tumor suppressor genes and their role on tumor microenvironment and immunity in lung squamous cell carcinoma. *Front Immunol* 2021;12:598671
18. Lim SM*, Pyo KH*, Soo RA, Cho BC. The promise of bispecific antibodies: clinical applications and challenges. *Cancer Treat Rev* 2021; 99: 102240.
19. Lee JY, Heo SG, Ahn BC, Hong MH, Cho BC, Lim SM*, Kim HR*. A phase II study of poziotinib in patients with recurrent and or metastatic head and neck squamous cell carcinoma. *Cancer Medicine* 2021; 10(20): 7012-7020.
20. Lim SM, Kim CG, Cho BC. Antibody-drug conjugates: a new addition to the treatment landscape of EGFR-mutant non-small cell lung cancer. *Cancer Res* 2022;82(1):18-20.
21. Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. Beyond Osimertinib: The development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. *J Thorac Oncol* 2021;16(5):740-763.